Astellas Shares Jump After Profits Fueled by Strong Drug Sales

Astellas Pharma Inc. rose the most in more than three months after quarterly profit exceeded analysts’ projections, driven by robust sales of its Padcev cancer treatment and Mirabegron used to control overactive bladders.

The stock rose as much as 7.2% in early morning trading in Tokyo on Thursday, the biggest intraday gain since April 10.